Al-Toubah T, et al. - Researchers retrospectively reviewed the records of 20 patients treated at a large referral center to identify patients seen between January 2008 and September 2018 with metastatic lung neuroendocrine neoplasms (NENs) who received treatment with capecitabine and temozolomide (CAPTEM). Fourteen had typical lung neuroendocrine tumors, five had atypical carcinoids, and one had disease defined as a large-cell neuroendocrine carcinoma. Nineteen patients were assessable for response. A total of 6 patients showed the best response of partial response per RECIST 1.1 criteria, 11 stable diseases, and 2 progressive diseases with an objective response rate of 30%, and disease control of 85%. Eleven patients ultimately progressed, only six of whom displayed progression per RECIST 1.1 criteria. The median progression-free survival and OS was 13 months and 68 months, respectively. The toxicity profile was mild with mainly grade 1, expected toxicities. Six patients needed dose decrease due to toxicity. Thus, in lung NENs, the CAPTEM regimen was concluded to be correlated with a high response rate and a comparatively tolerable toxicity profile.